CANCER

Genetic Technologies poised to unveil market moving news

Finfeed Archived May 07, 2019

Genetic Technologies Ltd (ASX:GTG) has established a Memorandum of Understanding with TGen, an Arizona-based biomedical research institute dedicated to conducting ground-breaking research with life changing results.

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

Next Investors Archived Apr 08, 2019

Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.

Genetic Technologies teams up with TGen

Finfeed Archived Apr 08, 2019

Genetic Technologies Ltd (ASX:GTG), a provider of world-leading genetic risk assessment test products, has established an important MoU with TGen, a major player in the US biomedical research industry.

Imugene releases encouraging HER-Vaxx trial results

Finfeed Archived Apr 02, 2019

Imugene Limited (ASX:IMU), a leading clinical stage immuno-oncology company, has today released new data on the Phase lb study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia.

First patient dosed in phase 2 trial with Imugene’s gastric cancer vaccine

Finfeed Archived Mar 14, 2019

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced dosing of the first patient in a in 68 patient randomised Phase 2 HER-Vaxx cancer trial.

Cashed up Imugene to present at American Association for Cancer Research

Finfeed Archived Feb 28, 2019

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), is developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors.

Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?

Next Investors Archived Jan 31, 2019

Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.

Imugene onboards renowned cancer scientist Michael Caligiuri

Finfeed Archived Jan 07, 2019

Imugene (ASX:IMU) has appointed world-renowned cancer researcher, Professor Michael Caligiuri — President of the City of Hope National Medical Center in LA — to its Scientific Advisory Board (SAB).

Imugene's promising trial results: five patients with >30% decrease in tumour size

Finfeed Archived Dec 17, 2018

Imugene (ASX:IMU) has met all study endpoints and produced positive top-line results from its Phase 1b study of its HER-Vaxx gastric cancer vaccine.

Can a tortoise cure cancer?

Finfeed Archived Dec 05, 2018

Long living tortoises may be the key to curing cancer and living longer.

Immuron appoints a new CEO to lead it into the future

Finfeed Archived Nov 19, 2018

Immuron (ASX:IMC) has just appointed a well-credentialled CEO to help it develop and commercialise its many treatments of many gut mediated diseases.

Imugene's gastric cancer immuno-oncology trial advances to Phase 2

Finfeed Archived Nov 13, 2018

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU), today announced preparations are underway to begin the Phase 2 study of its HER-Vaxx cancer vaccine in gastric cancer patients in early 2019.

Good run continues for Imugene with $1.85M R&D tax incentive

Finfeed Archived Nov 09, 2018

Imugene Limited (ASX:IMU) has today announced that it has received a research and development (R&D) tax refund of $1.85 million as part of the Australian government’s R&D tax incentive scheme. The incentive recognises the important immuno-oncology research activities undertaken by the ASX small cap during the financial year ended 30 June 2018.